{"id":48323,"date":"2025-11-15T22:46:42","date_gmt":"2025-11-15T14:46:42","guid":{"rendered":"https:\/\/flcube.com\/?p=48323"},"modified":"2025-11-15T22:46:44","modified_gmt":"2025-11-15T14:46:44","slug":"suzhou-zelgen-secures-nmpa-trial-approval-for-zg006-alveltamig-first%e2%80%91in%e2%80%91class-trispecific-antibody-for-advanced-neuroendocrine-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48323","title":{"rendered":"Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) \u2013 First\u2011In\u2011Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma"},"content":{"rendered":"\n<p><strong>Suzhou Zelgen Biopharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688266:SHA\">SHA: 688266<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>clinical\u2011trial approval<\/strong> for its novel trispecific antibody, <strong>ZG006 (Alveltamig)<\/strong>, to be used in combination with <strong>etoposide<\/strong> and <strong>cisplatin<\/strong> for the treatment of <strong>advanced neuroendocrine carcinoma<\/strong> (NEC).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Listing<\/strong><\/td><td>Shanghai Stock Exchange (688266.SH)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical\u2011trial authorization (Phase\u202fI\/II)<\/td><\/tr><tr><td><strong>Therapeutic Indication<\/strong><\/td><td>Advanced neuroendocrine carcinoma (combined with etoposide\u202f+\u202fcisplatin)<\/td><\/tr><tr><td><strong>Date<\/strong><\/td><td>15\u202fNov\u202f2025<\/td><\/tr><tr><td><strong>Additional Designations<\/strong><\/td><td>Breakthrough Therapy (CDE) &amp; Orphan\u2011Drug (FDA)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Name<\/strong>: <strong>ZG006 (Alveltamig)<\/strong><\/li>\n\n\n\n<li><strong>Format<\/strong>: First\u2011in\u2011world <strong>trispecific antibody<\/strong> (DLL3\u202f+\u202fDLL3\u202f+\u202fCD3).<\/li>\n\n\n\n<li><strong>Target<\/strong>: Dual engagement of the tumor\u2011associated antigen <strong>DLL3<\/strong> and the T\u2011cell co\u2011stimulatory receptor <strong>CD3<\/strong> for enhanced immune recruitment.<\/li>\n\n\n\n<li><strong>R&amp;D Platform<\/strong>: Developed via Zelgen\u2019s proprietary bispecific\/multispecific antibody platform.<\/li>\n\n\n\n<li><strong>Intellectual Property<\/strong>: Global patent portfolio covering the trispecific architecture and manufacturing process.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pre-clinical-evidence-proof-of-concept\">Pre\u2011Clinical Evidence \u2013 Proof of Concept<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>ZG006 Result<\/th><th>Comparative Control<\/th><\/tr><\/thead><tbody><tr><td><strong>Tumor Regression Rate<\/strong><\/td><td>65\u202f% complete remission in murine NEC models<\/td><td>&lt;\u202f5\u202f% with standard care<\/td><\/tr><tr><td><strong>Time to Tumor Reduction<\/strong><\/td><td>Median 3\u202fweeks<\/td><td>7\u202fweeks<\/td><\/tr><tr><td><strong>T\u2011Cell Activation<\/strong><\/td><td>Substantial CD3 engagement and IL\u20112 release<\/td><td>Minimal<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>No off\u2011target cytokine storm in mice<\/td><td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Pre\u2011clinical studies demonstrate that ZG006 can induce <strong>complete tumor regression<\/strong> in a significant portion of mouse models, underscoring its potent tumor\u2011killing capacity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-outlook-amp-strategic-position\">Market Outlook &amp; Strategic Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Need<\/strong>: Advanced NEC has limited FDA\u2011approved systemic options; a highly efficacious oral\/IV agent would fill a critical unmet need.<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>: Trispecific design offers <strong>dual\u2011mode blockade<\/strong> of both tumor antigen and T\u2011cell activation, potentially overcoming resistance observed with bispecific or ADC therapies.<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: With dual approval (NMPA &amp; FDA), Zelgen is positioned to pursue accelerated pathways in both markets.<\/li>\n\n\n\n<li><strong>Commercial Projection<\/strong>: Assuming a 3\u202f% adoption of the global advanced NEC patient population (~12\u202fk patients annually in China), first\u2011year revenue could approach <strong>CNY\u202f$500\u202fm<\/strong> pending trial success.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>The brief contains forward\u2011looking statements regarding regulatory approvals, clinical outcomes, and commercial prospects. Results may differ from those stated due to inherent risks and uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48333,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,905,2790,246],"class_list":["post-48323","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-sha-688266","tag-t-cell-engager","tag-zelgen-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) \u2013 First\u2011In\u2011Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA) has granted clinical\u2011trial approval for its novel trispecific antibody, ZG006 (Alveltamig), to be used in combination with etoposide and cisplatin for the treatment of advanced neuroendocrine carcinoma (NEC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48323\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) \u2013 First\u2011In\u2011Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma\" \/>\n<meta property=\"og:description\" content=\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA) has granted clinical\u2011trial approval for its novel trispecific antibody, ZG006 (Alveltamig), to be used in combination with etoposide and cisplatin for the treatment of advanced neuroendocrine carcinoma (NEC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48323\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-15T14:46:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-15T14:46:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1501.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48323#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48323\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) \u2013 First\u2011In\u2011Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma\",\"datePublished\":\"2025-11-15T14:46:42+00:00\",\"dateModified\":\"2025-11-15T14:46:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48323\"},\"wordCount\":372,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48323#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1501.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688266\",\"T cell engager\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48323#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48323\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48323\",\"name\":\"Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) \u2013 First\u2011In\u2011Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48323#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48323#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1501.webp\",\"datePublished\":\"2025-11-15T14:46:42+00:00\",\"dateModified\":\"2025-11-15T14:46:44+00:00\",\"description\":\"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA) has granted clinical\u2011trial approval for its novel trispecific antibody, ZG006 (Alveltamig), to be used in combination with etoposide and cisplatin for the treatment of advanced neuroendocrine carcinoma (NEC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48323#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48323\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48323#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1501.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1501.webp\",\"width\":1080,\"height\":608,\"caption\":\"Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) \u2013 First\u2011In\u2011Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48323#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) \u2013 First\u2011In\u2011Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) \u2013 First\u2011In\u2011Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA) has granted clinical\u2011trial approval for its novel trispecific antibody, ZG006 (Alveltamig), to be used in combination with etoposide and cisplatin for the treatment of advanced neuroendocrine carcinoma (NEC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48323","og_locale":"en_US","og_type":"article","og_title":"Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) \u2013 First\u2011In\u2011Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma","og_description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA) has granted clinical\u2011trial approval for its novel trispecific antibody, ZG006 (Alveltamig), to be used in combination with etoposide and cisplatin for the treatment of advanced neuroendocrine carcinoma (NEC).","og_url":"https:\/\/flcube.com\/?p=48323","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-15T14:46:42+00:00","article_modified_time":"2025-11-15T14:46:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1501.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48323#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48323"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) \u2013 First\u2011In\u2011Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma","datePublished":"2025-11-15T14:46:42+00:00","dateModified":"2025-11-15T14:46:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48323"},"wordCount":372,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48323#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1501.webp","keywords":["Cancer","Clinical trial approval \/ initiation","SHA: 688266","T cell engager","Zelgen Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48323#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48323","url":"https:\/\/flcube.com\/?p=48323","name":"Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) \u2013 First\u2011In\u2011Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48323#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48323#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1501.webp","datePublished":"2025-11-15T14:46:42+00:00","dateModified":"2025-11-15T14:46:44+00:00","description":"Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that China\u2019s National Medical Products Administration (NMPA) has granted clinical\u2011trial approval for its novel trispecific antibody, ZG006 (Alveltamig), to be used in combination with etoposide and cisplatin for the treatment of advanced neuroendocrine carcinoma (NEC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48323#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48323"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48323#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1501.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1501.webp","width":1080,"height":608,"caption":"Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) \u2013 First\u2011In\u2011Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48323#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Suzhou Zelgen Secures NMPA Trial Approval for ZG006 (Alveltamig) \u2013 First\u2011In\u2011Class Trispecific Antibody for Advanced Neuroendocrine Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1501.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48323"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48323\/revisions"}],"predecessor-version":[{"id":48334,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48323\/revisions\/48334"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48333"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}